Skip to main content

ORIGINAL RESEARCH article

Front. Vet. Sci.
Sec. Oncology in Veterinary Medicine
Volume 11 - 2024 | doi: 10.3389/fvets.2024.1439706

Single nucleotide polymorphism profiles of canine T-cell and null-cell lymphomas

Provisionally accepted
Sirintra Sirivisoot Sirintra Sirivisoot 1Tanit Kasantikul Tanit Kasantikul 2Somporn Techangamsuwan Somporn Techangamsuwan 1Anudep Rungsipipat Anudep Rungsipipat 1*
  • 1 Center of Excellence for Companion Animal Cancer, Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand
  • 2 Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Michigan State University, East Lansing, Illinois, United States

The final, formatted version of the article will be published soon.

    The histopathological classification of T-cell lymphoma (TCL) in humans has distinctive mutational genotyping that suggests different lymphomagenesis. A similar concept is assumed to be observed in dogs with different TCL phenotypes.Objective: This study aimed to identify the previously reported single nucleotide polymorphisms (SNPs) from both human beings and dogs in canine TCLs and null-cell lymphomas (NCLs) and to design compatible oligonucleotides from each variant based on the multiplex polymerase chain reaction. Method: Genomic DNA was extracted from 68 tumor specimens and five buffy coat samples from dogs with TCL. Four TCL subtypes and NCL were analyzed in 44 SNPs from 21 genes using the MassARRAY. Results: The greatest incidence of SNPs observed in all TCL subtypes and NCL were SATB1 c.1259A>C, KIT c.1275A>G, SEL1L c.2040+200C>G, and TP53 c.1024C>T, respectively. Some SNP locations were statistically significantly associated with NCL including MYC p.S75F (p = 0.0003), TP53 p.I149N (p = 0.030), PDCD1 p.F37LX (p = 0.012), and POT1 p.R583* (p = 0.012).Each TCL histological subtype and NCL is likely to contain distinctive mutational genetic profiles, which might play a role in lymphoma gene-risk factors and might be useful for selecting therapeutic target drugs for each canine patient.

    Keywords: cutaneous T-cell lymphoma, dog, Intestinal T-cell lymphoma, nodal T-cell lymphoma, null-cell lymphoma, snps

    Received: 28 May 2024; Accepted: 22 Jul 2024.

    Copyright: © 2024 Sirivisoot, Kasantikul, Techangamsuwan and Rungsipipat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Anudep Rungsipipat, Center of Excellence for Companion Animal Cancer, Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.